MedPath

Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome

Not Applicable
Completed
Conditions
HIV Infections
Histoplasmosis
Registration Number
NCT00000627
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

To evaluate the use of fluconazole as (1) induction therapy in histoplasmosis, (2) maintenance therapy to prevent relapse of histoplasmosis.

Histoplasmosis is a serious opportunistic infection in patients with AIDS. Fluconazole is a triazole antifungal agent that has been used successfully in the treatment of experimental histoplasmosis in animals, but has not been completely evaluated in patients for this use. It has been approved by the Food and Drug Administration for certain other fungal infections. Nevertheless, physicians are prescribing it to their patients with histoplasmosis. This is a pilot study to examine the role of fluconazole for treating histoplasmosis in AIDS patients.

Detailed Description

Histoplasmosis is a serious opportunistic infection in patients with AIDS. Fluconazole is a triazole antifungal agent that has been used successfully in the treatment of experimental histoplasmosis in animals, but has not been completely evaluated in patients for this use. It has been approved by the Food and Drug Administration for certain other fungal infections. Nevertheless, physicians are prescribing it to their patients with histoplasmosis. This is a pilot study to examine the role of fluconazole for treating histoplasmosis in AIDS patients.

At least 40 patients with AIDS and an initial episode of disseminated histoplasmosis are selected for the study. Patients receive fluconazole for a total of 12 weeks. Patients who are unable to take the drug orally may receive it intravenously until oral administration is possible. Patients are evaluated at weeks 0, 1, 2, 4, 8, and 12. Patients who are doing well without evidence of clinical failure or dose-limiting toxicity are permitted to continue maintenance therapy to prevent relapse at a reduced dose for an additional 12 months; those who relapse on the reduced dose are permitted to receive re-induction with a higher dose.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
90
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (23)

Methodist Hosp of Indiana / Life Care Clinic

🇺🇸

Indianapolis, Indiana, United States

San Francisco Veterans Administration Med Ctr

🇺🇸

San Francisco, California, United States

Montefiore Med Ctr / Bronx Municipal Hosp

🇺🇸

Bronx, New York, United States

Univ of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

Univ of Southern California / LA County USC Med Ctr

🇺🇸

Los Angeles, California, United States

Indiana Univ Hosp

🇺🇸

Indianapolis, Indiana, United States

Baystate Med Ctr of Springfield

🇺🇸

Springfield, Massachusetts, United States

Infectious Diseases Association / Research Med Ctr

🇺🇸

Kansas City, Missouri, United States

St Louis Regional Hosp / St Louis Regional Med Ctr

🇺🇸

Saint Louis, Missouri, United States

Worcester Memorial Hosp / Med Ctr of Cntrl MA-Memorial

🇺🇸

Worcester, Massachusetts, United States

Univ of Missouri at Kansas City School of Medicine

🇺🇸

Kansas City, Missouri, United States

Montefiore Drug Treatment Ctr / Bronx Municipal Hosp

🇺🇸

Bronx, New York, United States

Montefiore Family Health Ctr / Bronx Municipal Hosp

🇺🇸

Bronx, New York, United States

North Central Bronx Hosp / Bronx Municipal Hosp

🇺🇸

Bronx, New York, United States

Samaritan Village Inc / Bronx Municipal Hosp

🇺🇸

Bronx, New York, United States

Mount Sinai Med Ctr

🇺🇸

New York, New York, United States

Beth Israel Med Ctr

🇺🇸

New York, New York, United States

Saint Luke's - Roosevelt Hosp Ctr

🇺🇸

New York, New York, United States

Cornell Univ Med Ctr

🇺🇸

New York, New York, United States

Univ TX Health Science Ctr

🇺🇸

Houston, Texas, United States

Ohio State Univ Hosp Clinic

🇺🇸

Columbus, Ohio, United States

Julio Arroyo

🇺🇸

West Columbia, South Carolina, United States

Houston Veterans Administration Med Ctr

🇺🇸

Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath